Analysts Set Cellebrite DI Ltd. (NASDAQ:CLBT) Price Target at $21.40

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT) have earned a consensus recommendation of “Moderate Buy” from the six analysts that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $21.40.

A number of analysts have recently commented on the stock. DA Davidson assumed coverage on shares of Cellebrite DI in a report on Wednesday, May 27th. They set a “buy” rating and a $20.00 target price on the stock. Weiss Ratings upgraded shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 18th. Wall Street Zen upgraded shares of Cellebrite DI from a “sell” rating to a “hold” rating in a report on Sunday, March 15th. Finally, Needham & Company LLC dropped their price target on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, May 15th.

Cellebrite DI Trading Down 3.2%

Shares of CLBT stock opened at $12.42 on Tuesday. Cellebrite DI has a 12 month low of $11.02 and a 12 month high of $19.98. The stock has a market cap of $3.10 billion, a PE ratio of 44.36, a price-to-earnings-growth ratio of 1.59 and a beta of 1.17. The company’s fifty day moving average price is $13.12 and its 200-day moving average price is $14.85.

Insider Transactions at Cellebrite DI

In related news, CRO Marcus Jewell sold 12,658 shares of the company’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $12.77, for a total value of $161,642.66. Following the transaction, the executive owned 440,101 shares in the company, valued at $5,620,089.77. The trade was a 2.80% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last quarter, insiders have sold 13,269 shares of company stock valued at $169,592. Insiders own 5.70% of the company’s stock.

Hedge Funds Weigh In On Cellebrite DI

Hedge funds have recently bought and sold shares of the company. Towarzystwo Funduszy Inwestycyjnych PZU SA boosted its stake in Cellebrite DI by 81.0% in the 4th quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock worth $34,000 after purchasing an additional 850 shares in the last quarter. Advisory Services Network LLC bought a new position in Cellebrite DI during the 3rd quarter valued at about $40,000. CWM LLC lifted its stake in Cellebrite DI by 57.0% during the 4th quarter. CWM LLC now owns 2,449 shares of the company’s stock valued at $44,000 after acquiring an additional 889 shares during the period. First Horizon Corp lifted its stake in Cellebrite DI by 421.8% during the 4th quarter. First Horizon Corp now owns 2,891 shares of the company’s stock valued at $52,000 after acquiring an additional 2,337 shares during the period. Finally, Vestcor Inc bought a new position in Cellebrite DI during the 3rd quarter valued at about $70,000. Institutional investors own 45.88% of the company’s stock.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.